导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 2.59% | 1803/4773 |
| 近一周 | -3.36% | 4710/5465 |
| 近一月 | 0.42% | 594/5421 |
| 近一季 | 1.79% | 668/5231 |
| 近半年 | -3.98% | 2673/4920 |
| 近一年 | 2.63% | 2239/4394 |
| 近两年 | 24.07% | 2547/2954 |
| 近三年 | 15.75% | 1623/2253 |
| 成立以来 | 201.14% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
3.74% 670/4961 |
-9.93% 4007/5312 |
- - |
- - |
| 2025 | 2.56% 3177/4813 |
-2.59% 2923/3635 |
2.26% 1702/4076 |
2.25% 3819/4524 |
0.70% 1834/4813 |
| 2024 | 15.50% 921/3463 |
7.70% 230/2808 |
1.46% 468/3014 |
7.51% 2814/3129 |
-1.69% 1792/3463 |
| 2023 | 4.77% 217/2656 |
4.87% 859/2280 |
0.61% 301/2385 |
3.85% 169/2515 |
-4.38% 994/2655 |
| 2022 | -1.16% 46/2207 |
1.25% 105/1919 |
-0.90% 1659/2016 |
-1.96% 27/2113 |
0.48% 1489/2208 |
| 2021 | 22.54% 145/1822 |
4.55% 146/1255 |
10.38% 466/1330 |
6.78% 211/1466 |
-0.55% 1249/1822 |
| 2020 | 9.39% 844/1250 |
-9.47% 679/1028 |
6.10% 870/1067 |
9.82% 616/1164 |
3.70% 894/1184 |
| 2019 | 20.21% 669/1092 |
21.69% 594/754 |
-4.29% 426/804 |
-2.24% 691/850 |
5.58% 702/918 |
| 2018 | -16.89% 116/834 |
- - |
- - |
- - |
-7.09% 55/691 |
| 2017 | 18.66% 206/714 |
- - |
- - |
- - |
- - |
| 2016 | -7.45% 220/605 |
- - |
- - |
- - |
- - |
| 2015 | 27.09% 84/575 |
- - |
- - |
- - |
- - |
| 2014 | 52.30% 66/237 |
- - |
- - |
- - |
- - |
| 2013 | -7.98% 133/186 |
- - |
- - |
- - |
- - |
| 2012 | 6.92% 66/140 |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 万家中证红利ETF联接A VS. 长安沪深300非周期A(740101) |